In 2022, the worlds of technology and science will continue to merge at an unprecedented rate, allowing for the faster development and delivery of novel patient-centric treatments, such and cell and gene therapies. But novelty is naturally accompanied by risk. It is critical that biopharma companies collaborate with innovative manufacturing partners in this evolving environment.
Our CSO, Dr. Christian Schetter contributed to In Vivo’s Outlook 2022 publication. Find out more about how we are applying science in manufacturing to meet the complex challenges of tomorrow in Dr. Schetter’s Interview.
Rentschler Biopharma SE
Dr. Cora Kaiser
Senior Director Corporate Communication